Skip Ribbon Commands
Skip to main content


First in Texas to Robotically Perform SITRAL + TAVR During Same Procedure

Baylor Scott & White The Heart Hospital – Plano recently completed the first successful combined procedure in Texas that included surgical implantation of transcatheter valve in native mitral annual calcification (SITRAL) and transcatheter aortic valve replacement (TAVR) using robotic technology. Read the full article »​

WATCHMAN device​Stroke and Atrial Fibrillation: Beyond Meds

Atrial fibrillation (AF or Afib​​​) is the most common arrhythmia treated in clinical practice. Lifetime risk of AF is estimate to be 24% in elderly patients. Stroke​ is the most devastating complication of AF, with AF patients experiencing a fivefold higher risk of stroke and a twofold increased risk of all-cause mortality. Read the Beyond Meds full article »

Photograph courtesy of the Boston Scientific Corporation.

Team of surgeonsTeaching on the Cutting Edge

For nearly a decade, Baylor Scott & White The Heart Hospital – Plano has pursued innovation in cardiovascular healthcare, offering novel therapies and procedures for a variety of heart disease. The large volume of procedures and surgeries performed at Baylor Scott & White Heart – Plano​ provides a unique opportunity for cardiologists and cardiac surgeons to train the next generation of innovators in cardiovascular healthcare. Read the Teaching full article »

"Code Aorta" for Acute Aortic Dissections: Time is of the Essence

Aortic dissections have been described as ticking time bombs—the sooner patients with this condition are treated, the better the outcome. Read the full article on Code Aorta »​​

Highlighted below are a sample of our actively enrolling research trials:​

Heart Valve

  • Early TAVR
    Establish the safety and effectiveness of the Edwards SAPIEN 3™ (Edwards Lifesciences­™, Irvine, California)​ Transcatheter Heart Valve (THV) compared with clinical surveillance (CS) in asymptomatic patients with severe, calcific aortic stenosis.
  • PARTNER 3​ - Principal Investigators: David L. Brown, MD / Michael Mack, MD
    Establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve in low-risk patients requiring aortic valve replacement who have severe, calcific, symptomatic aortic stenosis.
  • TAVR in MAC (SITRAL) - Principal Investigator: Robert L. Smith, II, MD
    The purpose of this study is to establish the safety and feasibility of the Edwards SAPIEN 3 valve in subjects with mitral annular calcification (MAC) associated with mitral stenosis (MS) and/or mitral regurgitation who are at risk for mitral valve surgery due to the extent of calcification.

​Cardiothoracic & Vascular Surgery

  • GORE® TAG® TBE (Pivotal) - Principal Investigator​: William T. Brinkman, MD
    Determine whether the GORE® TAG® Thoracic Branch Endoprosthesis is safe and effective in treating lesions of the aortic arch and descending thoracic aorta.​


  • ​​Lariat® - ​Principal Investigator: Brian DeVille, MD
    To assess the utility of left atrial appendage ligation with the SentreHEART Lariat® device in improving the success of ablation in participants with persistent atrial fibrillation.​​
  • PRECEPT - Principal Investigator: Brian DeVille​​, MD
    Demonstrate the safety and effectiveness of the THERMOCOOL SMARTTOUCH® SF catheter in the treatment of drug refractory in symptomatic, persistent atrial fibrillation following standard electrophysiology mapping and RF ablation procedures.

Coronary Artery Disease

  • AFFECTS - Principal Investigator: David L. Brown, MD
    To correlate the Heartflow technology to gold standard of cardiac catheterization with FFR after a positive SPECT scan.
  • EVOLVE - Principal Investigator: Molly Szerlip, MD
    Assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with the SYNERGY™ Stent System.​

For a full list of our research trials​, and for information on enrollment, contact the Research Office at 469.814.4720 or send an e-mail to​.


Email Address: *

Clinical news